eyenovia-logo 3

2016 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015
11/28/16
Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of micro-formulation over conventional eyedroppers and addition of Scientific Advisory Board members
Eyenovia's study shows that conventional ophthalmic eye drops significantly overdose the eye and that equivalent, or greater, pharmacodynamic effect can be achieved with 80% less ocular exposure through Eyenovia's ophthalmic micro-formulation Prof. Robert N. Weinreb, Director, Shiley Eye Institute and Chair, Department of Ophthalmology, University of California, San Diego and Prof. Louis Pasquale, Director, Glaucoma Service, Massachusetts Eye and Ear and Professor of Ophthalmology, Harvard... 

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017     +1 (917) 289-1117

[email protected]